No­to­ri­ous ac­tivist in­vestor Carl Ic­ahn buys small stake in Al­ler­gan

Ac­tivist in­vestor Carl Ic­ahn has tak­en a small stake in Al­ler­gan, join­ing a grow­ing list of weighty share­hold­ers who could in­flu­ence the com­pa­ny’s strat­e­gy at a time when in­vestors are push­ing for changes.

With com­pe­ti­tion edg­ing in on its two top sell­ers — Botox and Resta­sis — Al­ler­gan $AGN has strug­gled to ap­pease its share­hold­ers with a plan of ac­tion. The com­pa­ny’s ef­fort to pro­tect its Resta­sis IP through the con­tro­ver­sial — and ul­ti­mate­ly failed — trib­al li­cens­ing strat­e­gy didn’t help mat­ters.

Brent Saun­ders

We don’t know the size of Ic­ahn’s stake, or what his plans might be for the com­pa­ny. But we do know Ic­ahn has been rather friend­ly in the past to Al­ler­gan CEO Brent Saun­ders, push­ing for him in 2013 to be­come CEO of For­est Lab­o­ra­to­ries (which through merg­ers and ac­qui­si­tions be­came Al­ler­gan).

Top share­hold­ers are look­ing for ac­tivist in­vestors to make some changes at the Dublin-based drug­mak­er, Bloomberg, which first re­port­ed the news, re­ports, cit­ing un­named sources “fa­mil­iar with the mat­ter.” In ad­di­tion to Ic­ahn, ac­tivist in­vestor Alex Den­ner at Saris­sa Cap­i­tal al­so has a stake in Al­ler­gan. Den­ner is known for be­ing Ic­ahn’s for­mer pro­tégé and for his his­to­ry of spurring ac­qui­si­tions at com­pa­nies in which he in­vests. His stake in Al­ler­gan is no­table even though its small, con­sid­er­ing Saris­sa’s fair­ly re­cent stake in Iron­wood, Al­ler­gan’s part­ner on IBS and con­sti­pa­tion drug Linzess.

David Tep­per

Plus, Ic­ahn’s in­vest­ment fol­l­lows David Tep­per’s 1% stake at Al­ler­gan. Tep­per, founder and pres­i­dent of Ap­paloosa, just made head­lines this Tues­day for his let­ter to Al­ler­gan push­ing the drug­mak­er to over­haul its man­age­ment.

“It is time for Al­ler­gan’s man­age­ment to con­cen­trate on run­ning a world class phar­ma­ceu­ti­cal and aes­thet­ics busi­ness and forego thoughts of, or the ex­hil­a­ra­tion from, an am­bi­tious ac­qui­si­tion strat­e­gy,” Tep­per wrote in a let­ter to Al­ler­gan’s board.

Among Tep­per’s sug­ges­tions was split­ting up the roles of CEO and chair­man, both of which are oc­cu­pied by Saun­ders at the mo­ment.

Ic­ahn, who had in­vest­ed in Al­ler­gan in the past, be­lieves the com­pa­ny’s stock is un­der­val­ued, the sources said, ask­ing not to be iden­ti­fied be­cause the mat­ter is con­fi­den­tial.

Al­ler­gan re­cent­ly did a strate­gic re­view of the com­pa­ny, com­ing out af­ter with plans to sell its women’s health and in­fec­tious dis­ease units to fo­cus on med­ical aes­thet­ics, CNS, eye care and GI — ar­eas in which the com­pa­ny be­lieves it’s com­pet­i­tive to ri­vals.

Al­ler­gan is­sued this state­ment in re­sponse to ques­tions about Ic­ahn’s stake:

“Al­ler­gan wel­comes all in­vest­ments in our com­pa­ny. We main­tain an ac­tive di­a­logue with our share­hold­ers and val­ue their con­struc­tive in­put and ideas on de­liv­er­ing long-term val­ue.”

The com­pa­ny’s stock is up 2% on the news.


Im­age: Carl Ic­ahn. GET­TY IM­AGES

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

As Themis gears up for a Phase III trial of its chikungunya vaccine, the Vienna-based biotech has closed out €40 million ($44 million) to foot the clinical and manufacturing bills.

Its heavyweight partners at Merck — which signed a pact around a mysterious “blockbuster indication” last month — jumped into the Series D, led by new investors Farallon Capital and Hadean Ventures. Adjuvant Capital also joined, as did current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences.